Adventhealth Orlando
Organisation
People
31 Aug 2026, reporter.nih.gov
27 Aug 2026, reporter.nih.gov
Director of translational neuroscience, 19 Aug 2026, reporter.nih.gov
Senior investigator (full professor), 7 Apr 2026, reporter.nih.gov
27 Feb 2026, reporter.nih.gov
Senior investigator, tri, 11 Sept 2025, reporter.nih.gov
Senior investigator, 26 Jun 2025, reporter.nih.gov
Associate investigator, 12 Jun 2024, reporter.nih.gov
Grants and prizes
National Institute of Diabetes and Digestive and Kidney Diseases
R03, Glucagon Like Peptide-1 Medicine Outcomes in Real World Patients with Type 1 Diabetes, R03DK145927, US$151.8k, 2026–2028, 31 Aug 2026, reporter.nih.gov
R01, Effects of Aerobic Exercise on Skeletal Muscle Remodeling in Colon Cancer, R01CA270274, US$675.7k, 2022–2027, 27 Aug 2026, reporter.nih.gov
R13, Physical Activity and Dementia Risk, R13AG104213, US$50k, 2026–2031, 19 Aug 2026, reporter.nih.gov
U01, Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer, U01CA271279, US$1.2m, 2022–2028, 10 Aug 2026, reporter.nih.gov
RF1, Examining the Persistence of Neurocognitive Benefits of Exercise, RF1AG083156, US$4.3m, 2023–2028, 6 Aug 2026, reporter.nih.gov
National Institute of Diabetes and Digestive and Kidney Diseases
K23, Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes, K23DK131327, US$197.9k, 2023–2028, 17 Apr 2026, reporter.nih.gov
National Institute of Diabetes and Digestive and Kidney Diseases
R01, Adipogenesis, triglyceride turnover and cellular composition of adipose tissue in response to endurance training (ATLAS), R01DK133529, US$696.4k, 2024–2029, 7 Apr 2026, reporter.nih.gov
National Institute of Diabetes and Digestive and Kidney Diseases
F32, Effects of exercise training on subcutaneous adipose tissue cellular heterogeneity in adults with obesity, F32DK146553, US$74.6k, 2026–2029, 27 Feb 2026, reporter.nih.gov
National Institute of Diabetes and Digestive and Kidney Diseases
U01, Ketone Monitoring Approaches for DKA Risk Mitigation in People with T1D on Adjunctive SGLT2 Inhibitors (KARMA), U01DK143384, US$2.5m, 2025–2028, 11 Sept 2025, reporter.nih.gov
R01, Examining the Persistence of Neurocognitive Benefits of Exercise, R01AG083156, US$2.3m, 2023–2026, 17 Jul 2025, reporter.nih.gov
R01, Impact of mitochondrial genetics on muscle oxidative capacity, fitness, and mobility in older adults, R01AG075081, US$572k, 2022–2027, 26 Jun 2025, reporter.nih.gov
R35, Physical Activity and Dementia: Mechanisms of Action, R35AG072307, US$627.9k, 2021–2026, 28 Apr 2025, reporter.nih.gov
R21, Exercise, Stress Biomarkers, and Alzheimer's Disease Neuropathology, R21AG087171, US$487.6k, 2024–2027, 12 Jun 2024, reporter.nih.gov
R01, Investigating the role of adipose tissue in mobility and aging (SOMMA-AT), R01AG066474, US$708.4k, 2020–2026, 29 May 2024, reporter.nih.gov